Major Depressive Disorder With Moderate To Severe Symptoms Therapeutics
1. Pristiq patent expiration
Treatment: For the approved uses and conditions of use, including depression; Maintenance treatment of major depressive disorder (mdd)
PRISTIQ's oppositions filed in EPO
PRISTIQ IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6673838 | PF PRISM CV | Succinate salt of O-desmethyl-venlafaxine |
Mar, 2022
(3 years ago) | |
| US8269040 | PF PRISM CV | Derivatives of venlafaxine and methods of preparing and using the same |
Jul, 2027
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6673838 | PF PRISM CV | Succinate salt of O-desmethyl-venlafaxine |
Feb, 2022
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 01, 2013 |
| New Indication(I-675) | Feb 14, 2016 |
| M(M-222) | Feb 06, 2021 |
Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient
NCE-1 date: 01 March, 2012
Market Authorisation Date: 20 August, 2014
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of PRISTIQ before it's drug patent expiration?
More Information on Dosage
PRISTIQ family patents
